Time Out: Talking Strategy For CRISPR’s Big 3 – Seeking Alpha
Wall Street Morning |
Time Out: Talking Strategy For CRISPR's Big 3
Seeking Alpha By Christopher Lew, Senior Analyst DeciBio Consulting. Intellia (NTLA), Editas (EDIT), and CRISPR Therapeutics (CRSP) grew rapidly in the last year, reaching market caps of ~$900M, ~$1.5B, and ~$2.1B, respectively, and all holding cash positions of … Financially Devastating or Fantastic? – Frontier Communications Corporation (FTR), CRISPR Therapeutics AG (CRSP) Analysts recommended an average rating score of 2.10 for CRISPR Therapeutics AG (CRSP) CRISPR Therapeutics (CRSP) Stock Price Down 1.3% |
